Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Afatinib: added benefit in certain mutations confirmed

2015-08-17 In advanced non-small cell lung cancer, the new tyrosine-kinase inhibitor is more effective than combination chemotherapy in patients with certain mutations.  read more Link to "Afatinib: added benefit in certain mutations confirmed"

Safinamide in Parkinson disease: no hint of added benefit

2015-08-17 Since relevant study data were not considered, the analyses in the dossier were incomplete regarding serious side effects in the comparator therapy, long-term data and other aspects.  read more Link to "Safinamide in Parkinson disease: no hint of added benefit"

Insulin degludec plus liraglutide: no hint of added benefit in type 2 diabetes

2015-08-03 Insulin degludec plus liraglutide: no hint of added benefit in type 2 diabetes due to lack of suitable studies.  read more Link to "Insulin degludec plus liraglutide: no hint of added benefit in type 2 diabetes"

Vortioxetine in depression: no hint of added benefit

2015-08-03 The dossier contained no suitable data for acute treatment or for relapse prevention. The evidence was only partly considered for the indirect comparison with citalopram.  read more Link to "Vortioxetine in depression: no hint of added benefit"

Dasabuvir and ombitasvir/paritaprevir/ritonavir: hint of added benefit in further patients

2015-07-16 Results of an indirect comparison subsequently submitted by the drug manufacturer show added benefit in one further group of hepatitis C patients. The extent remains unclear, however.  read more Link to "Dasabuvir and ombitasvir/paritaprevir/ritonavir: hint of added benefit in further patients"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

There are no actual comments.


Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Fixed-dose combination aclidinium bromide / formoterol (Duaklir Genuair, Brimica Genuair) for chronic obstructive pulmonary disease (COPD)

The fixed-dose combination of aclidinium bromide and formoterol (trade names: Duaklir Genuair and Brimica Genuair) has been approved since November 2014 for chronic obstructive pulmonary disease (COPD) in adults. Both drugs act to widen the airways in different ways.  read more (Link to "Fixed-dose combination aclidinium bromide / formoterol (Duaklir Genuair, Brimica Genuair) for chronic obstructive pulmonary disease (COPD)" – opens in a new window)

to top

Glossary entries